Investigational anti-inflammatory agents for the treatment of ischaemic brain injury

Expert Opinion on Investigational Drugs

Volumn 14, Issue 4, 2005, Pages 393-409

  Wang, Xinkang ^a  

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

Anti inflammation; Cerebral ischaemia; Inflammation; Investigational drug; Stroke; Therapy

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; 4 [3 [6 AMINO 9 (5 ETHYLCARBAMOYL 3,4 DIHYDROXYTETRAHYDRO 2 FURYL) 9H PURIN 2 YL] 2 PROPYNYL]CYCLOHEXANECARBOXYLIC ACID METHYL ESTER; 4 [4 (4 FLUOROPHENYL) 5 (2 METHOXY 4 PYRIMIDINYL) 1 IMIDAZOLYL]CYCLOHEXANOL; 4 PHOSPHONOMETHYLPIPECOLIC ACID; ADALIMUMAB; ADENOSINE A2A RECEPTOR ANTAGONIST; ALTEPLASE; ANATIBANT; ANTIINFLAMMATORY AGENT; APTIGANEL; AUTACOID; BRADYKININ B2 RECEPTOR ANTAGONIST; CASPASE INHIBITOR; CEP 1347; CITICOLINE; CLOMETHIAZOLE; CS 58125; CYCLOOXYGENASE 2 INHIBITOR; DPH 067517; EL 246; ELIPRODIL; ETANERCEPT; FOSPHENYTOIN SODIUM; GANGLIOSIDE GM1; GAVESTYNEL; GLYCINE RECEPTOR ANTAGONIST; IDN 5370; INFLIXIMAB; INTERCELLULAR ADHESION MOLECULE 1 ANTIBODY; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 1BETA CONVERTING ENZYME INHIBITOR; LACTACYSTIN BETA LACTONE; LUBELUZOLE; MITOGEN ACTIVATED PROTEIN KINASE P38 INHIBITOR; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY M60.1; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; NALMEFENE; NEUTRALIZING ANTIBODY; NIMODIPINE; NITRIC OXIDE SYNTHASE INHIBITOR; PEG 3935199; PRALNACASAN; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RGN 303; ROVELIZUMAB; S [2 (1 IMINOETHYLAMINO)ETHYL]HOMOCYSTEINE; SC 51; SCAVENGER; SCIO 323; SELECTIN ANTAGONIST; SL 327; TP 38; TRILIZAD; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME INHIBITOR; UNCLASSIFIED DRUG; WAY 197697;

BLOOD CLOT LYSIS; BRAIN INJURY; BRAIN ISCHEMIA; CAUSE OF DEATH; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; DISABILITY; DISEASE COURSE; DRUG EFFICACY; DRUG MECHANISM; EVIDENCE BASED MEDICINE; GENE FUNCTION; HUMAN; INFLAMMATION; MEDICAL DECISION MAKING; NONHUMAN; PATHOPHYSIOLOGY; REVIEW; SIDE EFFECT; TREATMENT PLANNING;

ADAM PROTEINS; ANIMALS; ANTI-INFLAMMATORY AGENTS; BRAIN; BRAIN ISCHEMIA; CLINICAL TRIALS; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; DRUG DESIGN; ENZYME INHIBITORS; HUMANS; INFLAMMATION; MITOGEN-ACTIVATED PROTEIN KINASES; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE II; PIPERIDINES; PROTEIN KINASE INHIBITORS; QUINOLINES; RECEPTORS, TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR-ALPHA;

EID: 19044368763     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.14.4.393     Document Type: Review

References (160)

1. SCHELLINGER PD, KASTE M, HACKE W:1 An update on thrombolytic therapy for acute stroke. Curr. Opin. Neurol. (2004) 17(1):69-77.
2. HACKE W, DONNAN G, FIESCHI C et al.: Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet (2004) 363(9411):768-774.
3. CAST COLLABORATIVE GROUP: Randomised placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke. CAST (Chinese Acute Stroke Trial) Collaborative Group. Lancet (1997) 349(9066):1641-1649.
4. CHEN ZM, SANDERCOCK P, PAN HC et al.: Indications for early aspirin use in acute ischemic stroke: a combined analysis of 40000 randomized patients from the Chinese acute stroke trial and the international stroke trial. On behalf of the CAST and IST collaborative groups. Stroke (2000) 31(6):1240-1249.
5. DIENER HC, CORTENS M, FORD G et al.: Lubeluzole in acute ischemic stroke treatment: a double-blind study with an 8-hour inclusion window comparing a 10-mg daily dose of lubeluzole with placebo. Stroke (2000) 31(11):2543-2551.
6. AHMED N, NASMAN P, WAHLGREN NG: Effect of intravenous nimodipine on blood pressure and outcome after acute stroke. Stroke (2000) 31(6):1250-1255.
7. CLARK WM, RAPS EC, TONG DC, KELLY RE: Cervene (nalmefene) in acute ischemic stroke: final results of a Phase III efficacy study. The Cervene Stroke Study Investigators. Stroke (2000) 31(6):1234-1239.
8. CLARK WM, WILLIAMS BJ, SELZER KA, ZWEIFLER RM, SABOUNJIAN LA, GAMMANS RE: A randomized efficacy trial of citicoline in patients with acute ischemic stroke. Stroke (1999) 30(12):2592-2597.
9. HALEY EC Jr, KASSELL NF, APPERSON-HANSEN C, MAILE MH, ALVES WM: A randomized, double-blind, vehicle-controlled trial of tirilazad mesylate in patients with aneurysmal subarachnoid hemorrhage: a cooperative study in North America. J. Neurosurg. (1997) 86(3):467-474.
10. DAVIS SM, LEES KR, ALBERS GW et al.: Selfotel in acute ischemic stroke: possible neurotoxic effects of an NMDA antagonist. Stroke (2000) 31(2):347-354.
11. LEES KR, ASPLUND K, CAROLEI A et al.: Glycine antagonist (gavestinel) in neuroprotection (GAIN International) in patients with acute stroke: a randomised controlled trial. GAIN International Investigators. Lancet. (2000) 355(9219):1949-1954.
12. ALBERS GW, GOLDSTEIN LB, HALL D, LESKO LM: Aptiganel Acute Stroke Investigators. Aptiganel hydrochloride in acute ischemic stroke: a randomized controlled trial. JAMA (2001) 286(21):2673-2682.
13. CANDELISE L, CICCONE A: Gangliosides for acute ischaemic stroke. Cochrane Database Syst. Rev. (2000) 2:CD000094.
14. WAHLGREN NG, RANASINHA KW, ROSOLACCI T et al.: Clomethiazole acute stroke study (CLASS): results of a randomized, controlled trial of clomethiazole versus placebo in 1360 acute stroke patients. Stroke (1999) 30(1):21-28.
15. ENLIMOMAB ACUTE STROKE TRIAL INVESTIGATORS: Use of anti-ICAM-1 therapy in ischemic stroke: results of the Enlimomab Acute Stroke Trial. Neurology (2001) 57(8):1428-1434.
16. FISHER M, SCHAEBITZ W: An overview of acute stroke therapy: past, present, and future. Arch. Intern. Med. (2000) 160(21):3196-3206.
17. BARONE FC, FEUERSTEIN GZ: Inflammatory mediators and stroke: new opportunities for novel therapeutics. J. Cereb. Blood Flow Metab. (1999) 19(8):819-834.
18. DEL ZOPPO G, GINIS I, HALLENBECK JM, IADECOLA C, WANG X, FEUERSTEIN GZ: Inflammation and stroke: putative role for cytokines, adhesion molecules and iNOS in brain response to ischemia. Brain Pathol. (2000) 10(1):95-112.
19. WANG X, FEUERSTEIN GZ: Role of immune and inflammatory mediators in CNS injury. Drug News Perspect. (2000) 13(3):133-140.
20. WANG CX, SHUAIB A: Involvement of inflammatory cytokines in central nervous system injury. Prog. Neurobiol. (2002) 67(2):161-172.
21. BARONE FC, PARSONS AA: Therapeutic potential of anti-inflammatory drugs in focal stroke. Expert Opin. Investig. Drugs (2000) 9(10):2281-2306.
22. ALLAN SM, ROTHWELL NJ: Inflammation in central nervous system injury. Philos. Trans R. Soc. Lond. B. Biol. Sci. (2003) 358(1438):1669-1677.
23. MOSKOWITZ MA, LO EH: Neurogenesis and Apoptotic Cell Death. Stroke (2003) 34(2):324-326.
24. LOVE S: Apoptosis and brain ischaemia. Prog. Neuropsychopharmacol. Biol. Psychiatry (2003) 27(2):267-282.
25. GLADSTONE DJ, BLACK SE, HAKIM AM et al.: Toward wisdom from failure: lessons from neuroprotective stroke trials and new therapeutic directions. Stroke (2002) 33(8):2123-2136.
26. LINDSBERG PJ, GRAU AJ: Inflammation and infections as risk factors for ischemic stroke. Stroke (2003) 34(10):2518-2532.
27. BOUTIN H, LEFEUVRE RA, HORAI R, ASANO M, IWAKURA Y, ROTHWELL NJ: Role of IL-1-α and IL-1β in ischemic brain damage. J. Neurosci. (2001) 21(15):5528-5534.
28. TOUZANI O, BOUTIN H, LEFEUVRE R et al.: Interleukin-1 influences ischemic brain damage in the mouse independently of the interleukin-1 Type I receptor. J. Neurosci. (2002) 22(1):38-43.
29. CLARK WM, RINKER LG, LESSOV NS et al.: Lack of interleukin-6 expression is not protective against focal central nervous system ischemia. Stroke (2000) 31(7):1715-1720.
30. GRILLI M, BARBIERI I, BASUDEV H et al.: Interleukin-10 modulates neuronal threshold of vulnerability to ischaemic damage. Eur. J. Neurosci. (2000) 12(7):2265-2272.
31. LAMBERTSEN KL, GREGERSEN R, MELDGAARD M et al.: A role for interferon-γ in focal cerebral ischemia in mice. J. Neuropathol. Exp. Neurol. (2004) 63(9):942-955.
32. GARY DS, BRUCE-KELLER AJ, KINDY MS, MATTSON MP: Ischemic and excitotoxic brain injury is enhanced in mice lacking the p55 tumor necrosis factor receptor. J. Cereb. Blood Flow Metab. (1998) 18(12):1283-1287.
33. MARTIN-VILLALBA A, HAHNE M, KLEBER S et al.: Therapeutic neutralization of CD95-ligand and TNF attenuates brain damage in stroke. Cell Death Differ. (2001) 8(7):679-686.
34. SORIANO SG, AMARAVADI LS, WANG YF et al.: Mice deficient in fractalkine are less susceptible to cerebral ischemia-reperfusion injury. J. Neuroimmunol. (2002) 125(1-2):59-65.
35. HUGHES PM, ALLEGRINI PR, RUDIN M, PERRY VH, MIR AK, WIESSNER C: Monocyte chemoattractant protein-1 deficiency is protective in a murine stroke model. J. Cereb. Blood Flow Metab. (2002) 22(3):308-317.
36. CHEN Y, HALLENBECK JM, RUETZLER C et al.: Overexpression of monocyte chemoattractant protein 1 in the brain exacerbates ischemic brain injury and is associated with recruitment of inflammatory cells. J. Cereb. Blood Flow Metab. (2003) 23(6):748-755.
37. TAKAMI S, MINAMI M, NAGATA I, NAMURA S, SATOH M: Chemokine receptor antagonist peptide, viral MIP-II, protects the brain against focal cerebral ischemia in mice. J. Cereb. Blood Flow Metab. (2001) 21(12):1430-1435.
38. PRESTIGIACOMO CJ, KIM SC, CONNOLLY ES Jr, LIAO H, YAN SF, PINSKY DJ: CD18-mediated neutrophil recruitment contributes to the pathogenesis of reperfused but not nonreperfused stroke. Stroke (1999) 30(5):1110-1117.
39. SORIANO SG, COXON A, WANG YF et al.: Mice deficient in Mac-1 (CD11b/CD18) are less susceptible to cerebral ischemia/reperfusion injury. Stroke (1999) 30(1):134-139.
40. CONNOLLY ES Jr, WINFREE CJ, SPRINGER TA et al.: Cerebral protection in homozygous null ICAM-1 mice after middle cerebral artery occlusion. Role of neutrophil adhesion in the pathogenesis of stroke. J. Clin. Invest. (1996) 97(1):209-216.
41. SORIANO SG, LIPTON SA, WANG YF et al.: Intercellular adhesion molecule-1-deficient mice are less susceptible to cerebral ischemia-reperfusion injury. Ann. Neurol. (1996) 39(5):618-624.
42. CONNOLLY ES Jr, WINFREE CJ, PRESTIGIACOMO CJ et al.: Exacerbation of cerebral injury in mice that express the P-selectin gene: identification of P-selectin blockade as a new target for the treatment of stroke. Circ. Res. (1997) 81(3):304-310.
43. WANG X, XU L, WANG H, YOUNG PR, GAESTEL M, FEUERSTEIN GZ: Mitogen-activated protein kinase-activated protein (MAPKAP) kinase 2 deficiency protects brain from ischemic injury in mice. J. Biol. Chem. (2002) 277(46):43968-43972.
44. KUAN CY, WHITMARSH AJ, YANG DD et al.: A critical role of neural-specific JNK3 for ischemic apoptosis. Proc. Natl. Acad. Sci. USA (2003) 100(25):15184-15189.
45. WANG X, XU L, WANG H, ZHAN Y, PURE E, FEUERSTEIN GZ: CD44 deficiency in mice protects brain from cerebral ischemia injury. J. Neurochem. (2002) 83(5):1172-1179.
46. HARA H, FINK K, ENDRES M et al.: Attenuation of transient focal cerebral ischemic injury in transgenic mice expressing a mutant ICE inhibitory protein. J. Cereb. Blood Flow Metab. (1997) 17(4):370-375.
47. SCHIELKE GP, YANG GY, SHIVERS BD, BETZ AL: Reduced ischemic brain injury in interleukin-1β converting enzyme-deficient mice. J. Cereb. Blood Flow Metab. (1998) 18(2):180-185.
48. IADECOLA C, ZHANG F. CASEY R, NAGAYAMA M, ROSS ME: Delayed reduction in ischemic brain injury and neurological deficits in mice lacking the inducible nitric oxide synthase gene. J. Neurosci. (1997) 17(23):9157-9164.
49. HUANG Z, HUANG PL, PANAHIAN N, DALKARA T, FISHMAN MC, MOSKOWITZ MA: Effects of cerebral ischemia in mice deficient in neuronal nitric oxide synthase. Science (1994) 265(5180):1883-1885.
50. IADECOLA C, NIWA K, NOGAWA S et al.: Reduced susceptibility to ischemic brain injury and N-methyl-D-aspartate-mediated neurotoxicity in cyclooxygenase-2-deficient mice. Proc. Natl. Acad. Sci. USA (2001) 98(3):1294-1299.
51. IADECOLA C, SALKOWSKI CA, ZHANG F et al.: The transcription factor interferon regulatory factor 1 is expressed after cerebral ischemia and contributes to ischemic brain injury. J. Exp. Med. (1999) 189(4):719-727.
52. PANG L, YE W, CHE XM, ROESSLER BJ, BETZ AL, YANG GY Reduction of inflammatory response in the mouse brain with adenoviral-mediated transforming growth factor-β1 expression. Stroke (2001) 32(2):544-552.
53. ESCH T, STEFANO G: Proinflammation: a common denominator or initiator of different pathophysiological disease processes. Med. Sci. Monit. (2002) 8(5):HY1-HY9.
54. RELTON JK, MARTIN D, THOMPSON RC, RUSSELL DA: Peripheral administration of interleukin-1 receptor antagonist inhibits brain damage after focal cerebral ischemia in the rat. Exp. Neurol. (1996) 138(2):206-213.
55. WANG X, FEUERSTEIN G Z, XU L et al.: Inhibition of tumor necrosis factor-alpha-converting enzyme by a selective antagonist protects brain from focal ischemic injury in rats. Mol. Pharmacol. (2004) 65(4):890-896.
56. SPERA PA, ELLISON JA, FEUERSTEIN GZ, BARONE FC: IL-10 reduces rat brain injury following focal stroke. Neurosci. Lett. (1998) 251(3):189-192.
57. RUOCCO A, NICOLE O, DOCAGNE F et al.: A transforming growth factor-β antagonist unmasks the neuroprotective role of this endogenous cyrokine in excitotoxic and ischemic brain injury. J. Cereb. Blood Flow Metab. (1999) 19(12):1345-1353.
58. HUANG J, CHOUDHRI TF, WINFREE CJ et al.: Postischemic cerebrovascular E-selectin expression mediates tissue injury in routine stroke. Stroke (2000) 31(12):3047-3053.
59. CHEN H, CHOPP M, ZHANG RL et al.: Anti-CD11b monoclonal antibody reduces ischemic cell damage after transient focal cerebral ischemia in rat. Ann. Neurol. (1994) 35(4):458-463.
60. ZHANG RL, CHOPP M, LI Y et al.: Anti-ICAM-1 antibody reduces ischemic cell damage after transient middle cerebral artery occlusion in the rat. Neurology (1994) 44(9):1747-1751.
61. BOWES MP, ZIVIIN JA, ROTHLEIN R: Monoclonal antibody to ICAM-1 adhesion site reduces neurological damage in a rabbit cerebral embolism stroke model. Exp. Neurol. (1993) 119(2):215-219.
62. MORI E, DEL ZOPPO GJ, CHAMBERS JD, COPELAND BR, ARFORS KE: Inhibition of polymorphonuclear leukocyte adherence suppresses no-reflow after focal cerebral ischemia in baboons. Stroke (1992) 23(5):712-718.
63. ALESSANDRINI A, NAMURA S, MOSKOWITZ MA, BONVENTRE JV: MEK1 protein kinase inhibition protects against damage resulting from focal cerebral ischemia. Proc. Natl. Acad. Sci. USA (1999) 96(22):12866-12869.
64. WANG X, WANG H, XU L et al.: Significant neuroprotection against ischemic brain injury by inhibition of the MEK1 protein kinase in mice: exploration of potential mechanism associated with apoptosis. J. Pharmacol. Exp. Ther. (2003) 304(1):172-178.
65. BARONE FC, IRVING FA, RAY AM et al.: SB 239063, a second-generation p38 mitogen-activated protein kinase inhibitor, reduces brain injury and neurological deficits in cerebral focal ischemia. J. Pharmacol. Exp. Ther. (2001) 296(2):312-321.
66. BORSELLO T, CLARKE PG, HIRT L et al: A peptide inhibitor of c-Jun N-terminal kinase protects against excitotoxicity and cerebral ischemia. Nat. Med. (2003) 9(9):1180-1186.
67. BOGOYEVITCH MA, BOEHM I, OAKLEY A, KETTERMAN AJ, BARR RK: Targeting the JNK MAPK cascade for inhibition: basic science and therapeutic potential. Biochim. Biophys. Acta. (2004) 1697(1-2):89-101.
68. MATSUO Y, ONODERA H, SHIGA Y et al.: Correlation between myeloperoxidose-quantified neutrophil accumulation and ischemic brain injury in the rat: effects of neutrophil depletion. Stroke (1994) 25(7):1469-1475.
69. BEAULIEU C, BUSCH E, ROTHER J, DE CRESPIGNY A, HSIA CJ, MOSELEY ME: Polynitroxyl albumin reduces infarct size in transient focal cerebral ischemia in the rat: potential mechanisms studied by magnetic resonance imaging. J. Cereb. Blood Flow Metab. (1998) 18(9):1022-1031.
70. IADECOLA C, ZHANG F, XU S, CASEY R, ROSS ME: Inducible nitric oxide synthase gene expression in brain following cerebral ischemia. J. Cereb. Blood Flow Metab. (1995) 15(3):378-384.
71. PARMENTIER S, BOHME GA, LEROUET D et al.: Selective inhibition of inducible nitric oxide synthase prevents ischaemic brain injury. Br. J. Pharmacol. (1999) 127(2):546-552.
72. NAKAYAMA M, UCHIMURA K, ZHU RL et al.: Cyclooxygenase-2 inhibition prevents delayed death of CA1 hippocampal neurons following global ischemia. Proc. Natl. Acad. Sci. USA (1998) 95(18):10954-10959.
73. PHILLIPS JB, WILLIAMS AJ, ADAMS J, ELLIOTT PJ, TORTELLA FC: Proteasome inhibitor PS519 reduces infarction and attenuates leukocyte infiltration in a rat model of focal cerebral ischemia. Stroke (2000) 31(7):1686-1693.
74. ZHANG L, ZHANG ZG, ZHANG RL et al.: Postischemic (6-hour) treatment with recombinant human tissue plasminogen activator and proteasome inhibitor PS-519 reduces infarction in a rat model of embolic focal cerebral ischemia. Stroke (2001) 32(12):2926-2931.
75. WILLIAMS AJ, BERTI R, DAVE JR, ELLIOT PJ, ADAMS J, TORTELLA FC: Delayed treatment of ischemia/reperfusion brain injury: extended therapeutic window with the proteosome inhibitor MLN519. Stroke (2004) 35(5):1186-1191.
76. HUANG J, AGUS DB, WINFREE CJ et al.: Dehydroascorbic acid, a blood-brain barrier transportable form of vitamin C, mediates potent cerebroprotection in experimental stroke. Proc. Natl. Acad. Sci. USA (2001) 98(20):11720-11724.
77. DEPLANQUE D, GELE P, PETRAULT O et al.: Peroxisome pre-treatment-activated receptor-α activation as a mechanism of preventive neuroprotection induced by chronic fenofibrate treatment. J. Neurosci. (2003) 23(15):6264-6271.
78. SHIBATA M, KUMAR SR, AMARA A et al.: Anti-inflammatory, antithrombotic, and neuroprotective effects of activated protein C in a murine model of focal ischemic stroke. Circulation (2001) 103(13):1799-1805.
79. RUDDLE NH: Tumor necrosis factor (TNF-α) and lymphotoxin (TNF-β). Curr. Opin. Immunol. (1992) 4(3):327-332.
80. BLACK RA, RAUCH CT, KOZLOSKY CJ et al.: A metalloproteinase disintegrin that releases tumour-necrosis factor-α from cells. Nature (1997) 385(6618):729-733.
81. ORLINICK JR, CHAO MV: TNF-related ligands and their receptors. Cell. Signal. (1998) 10(8):543-551.
82. GOODMAN JC, ROBERTSON CS, GROSSMAN RG, NARAYAN RK: Elevation of tumour necrosis factor in head injury. J. Neuroimmunol. (1990) 30(2-3):213-217.
83. SIREN AL, HELDMAN E, DORON D et al.: Release of proinflammatory and prothrombotic mediators in the brain and peripheral circulation in spontaneously hypertensive and normotensive Wistar-Kyoto rats. Stroke (1992) 23(11):1643-1651.
84. SHOHAMI E, NOVIKOV M, BASS R, YAMIN A, GALLILY R: Closed head injury triggers early production of TNF-α and IL-6 by brain tissue. J. Cereb. Blood Flow Metab. (1994) 14(4):615-619.
85. FAN L, YOUNG PR, BARONE FC, FEUERSTEIN GZ, SMITH DH, MCINTOSH TK: Experimental traumatic brain injury induces differential expression of TNF-α mRNA in the CNS. Mol. Brain Res. (1996) 36(2):287-291.
86. LIU T, CLARK RK, MCDONNELL PC et al.: Tumour necrosis factor α expression in ischemic neurons. Stroke (1994) 25(7):1481-1488.
87. WANG X, YUE TL, BARONE FC, WHITE R, YOUNG PR, FEUERSTEIN GZ: Concomitant cortical expression of TNF-α and IL-1β mRNA following transient focal ischemia. Mol. Chem. Neuropathol. (1994) 23(2-3):103-114.
88. BUTTINI M, APPEL K, SAUATER A, GEBICKE-HAERTER P-J, BODDEKE HW: Expression of tumour necrosis factor alpha after focal cerebral ischemia in the rat. Neuroscience (1996) 71(1):1-16.
89. BARONE FC, ARVIN B, WHITE RF et al.: Tumour necrosis factor α. A mediator of focal ischemic brain injury. Stroke (1997) 28(6):1233-1244.
90. FEUERSTEIN GZ, WANG XK, BARONE FC: Inflammatory mediators of ischemic injury: cyrokine gene regulation in stroke. In: Cerebrovascular Disease: Pathophysiology, Diagnosis and Management. Ginsberg MD, Bogousslavsky J (Eds), Blackwell Science, Inc. (1998):507-531.
91. ROSENBERG GA, ESTRADA EY, DENCOFF JE: Matrix metalloproteinases and TIMPs are associated with blood-brain barrier opening after reperfusion in rat brain. Stroke (1998) 29(10):2189-2195.
92. KOUWENHOVEN M, CARLSTROM C, OZENCI V, LINK H: Matrix metalloproteinase and cytokine profiles in monocytes over the course of stroke. J. Clin. Immunol. (2001) 21(5):365-375.
93. ROBBINS DS, SHIRAZI Y, DRYDALE BE, LIEBERMAN A, SHIN HS, SHIN ML: Production of cytotoxic factor for oligodendrocytes by stimulated astrocytes. J. Immunol. (1987) 139(8):2593-2597.
94. SHOHAMI E, BASS R, WALLACH D, YAMIN A, GALLILY R: Inhibition of tumour necrosis factor-α (TNF-α) activity in rat brain is associated with cerebroprotection after closed head injury. J. Cereb. Blood Flow Metab. (1996) 16(3):378-384.
95. NAWASHIRO H, MARTIN D, HALLENBECK JM: Inhibition of tumour necrosis factor and amelioration of brain infarction in mice. J. Cereb. Blood Flow Metab. (1997) 17(2):229-232.
96. NAWASHIRO H, TASAKI K, RUETZLER CA, HALLENBECK JM: TNF-α pre-treatment induces protective effects against focal cerebral ischemia in mice. J. Cereb. Blood Flow Metab. (1997) 17(5):483-490.
97. DAWSON DA, MARTIN D, HALLENBECK JM: Inhibition of tumour necrosis factor-α reduces focal cerebral ischemic injury in the spontaneously hypertensive rat. Neurosci. Lett. (1996) 218(1):41-44.
98. ELLIOTT MJ, MAINI RN, FELDMANN M et al.: Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor α (cA2) versus placebo in rheumatoid arthritis. Lancet (1994) 344(8930):1105-1110.
99. MORELAND LW, BAUMGARTNER SW, SCHIFF MH et al.: Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N. Engl. J. Med. (1997) 337(3):141-147.
100. FURST DE, SCHIFF MH, FLEISCHMANN RM et al.: Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis). J. Rheumatol. (2003) 30(12):2563-2571.
101. ROTHWELL NJ: Functions and mechanism of interleukin-1 in the brain. Trends Pharmacol. Sci. (1991) 12(11):430-435.
102. DINARELLO CA: Interleukin-1 and interleukin-1 antagonism. Blood (1991) 77(8):1627-1652.
103. MINAMI M, KURAISHI Y, SATOH M: Effects of kainic acid on messenger RNA levels of IL-1β, IL-6, TNF-α and LIF in the rat brain. Biochem. Biophys. Res. Commun. (1991) 176(2):593-598.
104. BUTTINI M, BODDEKI H: Peripheral lipopolysaccharide stimulations induces interleukin-β mRNA in rat brain microglial cells. Neuroscience (1995) 65(2):523-530.
105. MINAMI M, KURAISHI Y, YABUUCHI K, YAMAZAKI A, SATOH M: Induction of interleukin-1β mRNA in rat brain after transient forebrain ischemia. J. Neurochem. (1992) 58(1):390-392.
106. LIU T, McDONNELL PC, YOUNG PR et al.: Interleukin-1β mRNA expression in ischemic rat cortex. Stroke (1993) 24(11):1746-1751.
107. ROTHWELL NJ, LUHESHI GN: Interleukin 1 in the brain: biology, pathology and therapeutic target. Trends Neurosci. (2000) 23(12):618-625.
108. YAMASAKI Y, MATSUURA N, SHOZUHARA H, ONODERA H, ITOYAMA Y, KOGURE K: Interleukin-1 as a pathogenetic mediator of ischemic brain damage in the rats. Stroke (1995) 26(4):676-681.
109. WANG X, BARONE FC, AIYAR NV, FEUERSTEIN GZ: Increased interleukin-1 receptor and interleukin-1 receptor antagonist gene expression after focal stroke. Stroke (1997) 28(1):155-162.
110. ROTHWELL NJ, RELTON JK: Involvement of interleukin-1 and lipocortin-1 in ischemic brain damage. Cerebrovas. Brain Metab. Rev. (1993) 5(3):178-198.
111. LODDICK SA, ROTHWELL NJ: Neuroprotective effects of human recombinant interleukin-1 receptor antagonist in focal ischemia in the rat. J. Cereb. Blood Flow Metab. (1996) 16(5):932-940.
112. MARTIN D, CHINOOKOSWONG N, MILLER G: The interleukin-1 receptor antagonist (rhIL-1ra) protects against cerebral infarction in a rat model of hypoxia-ischemia. Exp. Neurol. (1995) 130(2):362-367.
113. BETZ AL, YANG GY, DAVIDSON BL: Attenuation of stroke in rats using an adenoviral vector to induce overexpression of interleukin-1 receptor antagonist in brain. J. Cereb. Blood Flow Metab. (1995) 15(4):547-551.
114. BARONE FC, WHITE RF, SPERA PA, CURRIE RW, WANG X, FEUERSTEIN GZ: Ischemic preconditioning and brain tolerance: temporal histologic and functional outcomes, protein synthesis requirement, and IL- 1ra and early gene expression. Stroke (1998) 29(9):1937-1951.
115. BRESNIHAN B: The safety and efficacy of interleukin-1 receptor antagonist in the treatment of rheumatoid arthritis. Semin. Arthritis Rheum. (2001) 30(5 Suppl. 2):17-20.
116. BEEKHUIZEN H, VAN FURTH R: Monocyte adherence to human vascular endothelium. J. Leukoc. Biol. (1993) 54(4):363-378.
117. GRANGER DN, KVIETYS PR, PERRY MA: Leukocyte-endothelial cell adhesion induced by ischemia and reperfusion. Can. J. Physiol. Pharmacol. (1993) 71(1):67-75.
118. WANG X, SIREN A-L, YUE T-L, BARONE FC, FEUERSTEIN GZ: Upregulation of intracellular adhesion molecule-1 (ICAM1) on brain microvascular endothelial cells in rat ischemic cortex. Mol. Brain Res. (1994) 26(1-2):61-68.
119. WANG X, YUE T-L, BARONE FC, FEUERSTEIN GZ: Demonstration of increased endothelial-leukocyte adhesion molecule 1 mRNA expression in rat ischemic cortex. Stroke (1995) 26(9):1665-1669.
120. OKADA Y, COPELAND BR, MORI E, TUNG MM, THOMAS WS, DEL ZOPPA GZ: P-selectin and intercellular adhesion molecule-1 expression after focal brain ischemia and reperfusion. Stroke (1994) 25(1):202-211.
121. CHOPP M, LI Y, JIANG N, ZHANG RL, PROSTAK J: Antibodies against adhesion molecules reduce apoptosis after transient middle cerebral artery occlusion in rat brain. J. Cereb. Blood Flow Metab. (1996) 16(4):578-584.
122. CHOPP M, ZHANG RL, CHEN H, LI Y, JIANG N, RUSCHE RJ: Post ischemic administration of an anti-MAC-1 antibody reduces ischemic cell damage after transient middle cerebral artery occlusion in the rat. Stroke (1994) 25(4):869-876.
123. JIANG N, MOYLE M, SOULE HR, ROTE WE, CHOPP M: Neutrophil inhibitory factor is neuroprotective after focal ischemia in rats. Ann. Neurol. (1995) 38(6):935-942.
124. CLARK WM, MADDEN KP, ROTHLEIN R, ZIVIN JA: Reduction of central nervous system ischemic injury by monoclonal antibody to intercellular adhesion molecule. J. Neurosurg. (1991) 75(4):623-627.
125. ZHANG RL, CHOPP M, JIANG N et al.: Anti-intercellular adhesion molecule-1 antibody reduces ischemic cell damage after transient but not permanent middle cerebral artery occlusion in the Wistar rat. Stroke (1995) 26(8):1438-1443.
126. ZHANG RL, ZHANG ZG, CHOPP M: Increased therapeutic efficacy with rt-PA and anti-CD18 antibody treatment of stroke in the rat. Neurology (1999) 52(2):273-279.
127. ISHIKAWA M, ZHANG JH, NANDA A, GRANGER DN: Inflammatory responses to ischemia and reperfusion in the cerebral microcirculation. Front. Biosci. (2004) 9:1339-1347.
128. BOWES MP, ROTHLEIN R, FAGAN SC, ZIVIN JA: Monoclonal antibodies preventing leukocyte activation reduce experimental neurologic injury and enhance efficacy of thrombolytic therapy. Neurology (1995) 45(4):815-819.
129. HARTL R, SCHURER L, SCHMID-SCHONBEIN GW, DEL ZOPPO GJ: Experimental antileukocyte interventions in cerebral ischemia. J. Cereb. Blood Flow Metab. (1996) 16(6):1108-1119.
130. HAYWARD NJ, ELLIOTT PJ, SAWYER SD, BRONSON RT, BARTUS RT: Lack of evidence for neutrophil participation during infarct formation following focal cerebral ischemia in the rat. Exp. Neurol. (1996) 139(2):188-202.
131. FURUYA K, TAKEDA H, AZHAR S et al.: Examination of several potential mechanisms for the negative outcome in a clinical stroke trial of enlimomab, a murine anti-human intercellular adhesion molecule-1 antibody: a bedside-to-bench study. Stroke (2001) 32(11):2665-2674.
132. GRIFFITH OW, STUEHR DJ: Nitric oxide synthases: properties and catalytic mechanism. Ann. Rev. Physiol. (1995) 57:707-736.
133. HUANG Z, HUANG PL, MA J et al.: Enlarged infarcts in endothelial nitric oxide synthase knockout mice are attenuated by nitro-L-arginine. J. Cereb. Blood Flow Metab. (1996) 16(5):981-987.
134. IADECOLA C: Bright and dark sides of nitric oxide in ischemic brain damage. Trends Neurosci. (1997) 20(3):132-138.
135. IADECOLA C, XU X, ZHANG F, EL-FAKAHANY EE, ROSS ME: Marked induction of calcium-independent nitric oxide synthase activity after focal cerebral ischemia. J. Cereb. Blood Flow Metab. (1995) 15(1):52-59.
136. IADECOLA C, ZHANG F, CASEY R, CLARK HB, ROSS ME: Inducible nitric oxide synthase gene expression in vascular cells after transient focal cerebral ischemia. Stroke (1996) 27(8):1373-1380.
137. GRANDATI M, VERRECCHIA C, REVAUD ML, ALLIX M, BOULU RG, PLOTKINE M: Calcium-independent NO-synthase activity and nitrites/nitrates production in transient focal cerebral ischaemia in mice. Br. J. Pharmacol. (1997) 122(4):625-630.
138. FORSTER C, CLARK HB, ROSS ME, IADECOLA C: Inducible nitric oxide synthase expression in human cerebral infarcts. Acta Neuropathol. (1999) 97(3):215-220.
139. SMITH WL, MARNETT LJ: Prostaglandin endoperoxide synthase: structure and catalysis. Biochim. Biophys. Acta (1991) 1083(1):1-17.
140. PLANAS AM, SORIANO MA, RODRIGUEZ-FARRE E, FERRER I: Induction of cyclooxygenase-2 mRNA and protein following transient focal ischemia in the rat brain. Neurosci. Lett. (1995) 200(3):187-190.
141. MIETTINEN S, FUSCO FR, YRJANHEIKKI J et al.: Spreading depression and focal brain ischemia induce cyclooxygenase-2 in cortical neurons through N-methyl-D-aspartic acid-receptors and phospholipase A2. Proc. Natl. Acad. Sci. USA (1997) 94(12):6500-6505.
142. NOGAWA S, ZHANG F, ROSS ME, IADECOLA C: Cyclo-oxygenase-2 gene expression in neurons contributes to ischemic brain damage. J. Neurosci. (1997) 17(8):2746-2755.
143. NOGAWA S, FORSTER C, ZHANG F, NAGAYAMA M, ROSS ME, IADECOLA C: Interaction between inducible nitric oxide synthase and cyclooxygenase-2 after cerebral ischemia. Proc. Natl. Acad. Sci. USA (1998) 95(18):10966-10971.
144. IADECOLA C, FORSTER C, NOGAWA S, CLARK HB, ROSS ME: Cyclooxygenase immunoreactivity in the human brain following cerebral ischemia. Acta Neuropathol. (1999) 98(1):9-14.
145. SALVEMINI D, MASFERRER JL: Interactions of nitric oxide with cyclooxygenase: in vitro, ex vivo, and in vivo studies. Methods Enzymol. (1996) 269:12-25.
146. IADECOLA C, GORELICK PB: The Janus face of cyclooxygenase-2 in ischemic stroke: shifting toward downstream targets. Stroke (2005) 36(2):182-185.
147. GARRINGTON TP, JOHNSON GL: Organization and regulation of mitogen-activated protein kinase signaling pathways. Curr. Opin. Cell Biol. (1999) 11(2):211-218.
148. SEGER R, KREBS EG: The MAPK signalling cascade. FASEB J. (1995) 9(9):726-735.
149. SKAPER SD, WALSH FS: Neurotrophic molecules: strategies for designing effective therapeutic molecules in neurodegeneration. Mol. Cell Neurosci. (1998) 12(4-5):179-193.
150. SLEVIN M, KRUPINSKI J, SLOWIK A, RUBIO F, SZCZUDLIK A, GAFFNEY J: Activation of MAP kinase (ERK-1/ERK-2), tyrosine kinase and VEGF in the human brain following acute ischaemic stroke. Neuroreport (2000) 11(12):2759-2764.
151. SUGINO T, NOZAKI K, TAKAGI Y et al.: Activation of mitogen-activated protein kinases after transient forebrain ischemia in gerbil hippocampus. J. Neurosci. (2000) 20(12):4506-4514.
152. IRVING EA, BARONE FC, REITH AD, HADINGHAM SJ, PARSONS AA: Differential activation of MAPK/ERK and p38/SAPK in neurones and glia following focal cerebral ischaemia in the rat. Brain Res. Mol. Brain Res. (2000) 77(1):65-75.
153. LEE JC, LAYDON JT, McDONNELL PC et al.: A protein kinase involved in the regulation of inflammatory cytokine biosynthesis. Nature (1994) 372:739-746.
154. PIAO CS, KIM JB, HAN PL, LEE JK: Administration of the p38 MAPK inhibitor SB203580 affords brain protection with a wide therapeutic window against focal ischemic insult. J. Neurosci. Res. (2003) 73(4):537-544.
155. LENNMYR F, ERICSSON A, GERWINS P, AFILSTROM H, TERENT A: Increased brain injury and vascular leakage after pre-treatment with p38-inhibitor SB203580 in transient ischemia. Acta Neurol. Scand. (2003) 108(5):339-345.
156. WANG ZQ, WU DC, HUANG FP, YANG GY: Inhibition of MEK/ERK 1/2 pathway reduces pro-inflammatory cytokine interleukin-1 expression in focal cerebral ischemia. Brain Res. (2004) 996(1):55-66.
157. OHTSUKI T, RUETZLER CA, TASAKI K, HALLENBECK JM: Interleukin-1 mediates induction of tolerance to global ischemia in gerbil hippocampal CA1 neurons. J. Cereb. Blood Flow Metab. (1996) 16(6):1137-1142.
158. TASAKI K, RUETZLER CA, OHTSUKI T, MARTIN D, NAWASHIRO H, HALLENBECK JM: Lipopolysaccharide pre-treatment induces resistance against subsequent focal cerebral ischemic damage in spontaneously hypertensive rats. Brain Res. (1997) 748(1-2):267-270.
159. VILA N, CASTILLO J, DAVALOS A, ESTEVE A, PLANAS AM, CHAMORRO A: Levels of anti-inflammatory cytokines and neurological worsening in acute ischemic stroke. Stroke (2003) 34(3):671-675.
160. LEGOS JJ, BARONE FC: Update on pharmacological strategies for stroke: prevention, acute intervention and regeneration. Curr. Opin. Investig. Drugs (2003) 4(7):847-858.